Sachiko Ozawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1248973/publications.pdf

Version: 2024-02-01

82 papers 3,033 citations

26 h-index 51 g-index

84 all docs

84 docs citations

84 times ranked 4135 citing authors

#	Article	IF	CITATIONS
1	Global Economic Burden of Norovirus Gastroenteritis. PLoS ONE, 2016, 11, e0151219.	1.1	385
2	Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011–20. Health Affairs, 2016, 35, 199-207.	2.5	239
3	How do you measure trust in the health system? A systematic review of the literature. Social Science and Medicine, 2013, 91, 10-14.	1.8	209
4	Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries. JAMA Network Open, 2018, 1, e181662.	2.8	197
5	Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic review. Vaccine, 2012, 31, 96-108.	1.7	184
6	COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. The Lancet Global Health, 2020, 8, e754-e755.	2.9	128
7	Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States. Health Affairs, 2016, 35, 2124-2132.	2.5	119
8	Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001–2020. Bulletin of the World Health Organization, 2017, 95, 629-638.	1.5	109
9	Public trust and vaccine acceptance-international perspectives. Human Vaccines and Immunotherapeutics, 2013, 9, 1774-1778.	1.4	99
10	Estimated Economic Benefits During The â€~Decade Of Vaccines' Include Treatment Savings, Gains In Labor Productivity. Health Affairs, 2011, 30, 1021-1028.	2.5	77
11	Costs of vaccine programs across 94 low- and middle-income countries. Vaccine, 2015, 33, A99-A108.	1.7	68
12	Exploring pathways for building trust in vaccination and strengthening health system resilience. BMC Health Services Research, 2016, 16 , 639 .	0.9	63
13	10 best resources on … mixed methods research in health systems. Health Policy and Planning, 2014, 29, 323-327.	1.0	57
14	Access to medicines through health systems in low- and middle-income countries. Health Policy and Planning, 2019, 34, iii1-iii3.	1.0	56
15	Comparison of trust in public vs private health care providers in rural Cambodia. Health Policy and Planning, 2011, 26, i20-i29.	1.0	55
16	Decision-Making Criteria among National Policymakers in Five Countries: A Discrete Choice Experiment Eliciting Relative Preferences for Equity and Efficiency. Value in Health, 2012, 15, 534-539.	0.1	53
17	During The â€~Decade Of Vaccines,' The Lives Of 6.4ÂMillion Children Valued At \$231ÂBillion Could Be Saved. Health Affairs, 2011, 30, 1010-1020.	2.5	51
18	Reassessing the value of vaccines. The Lancet Global Health, 2014, 2, e251-e252.	2.9	49

#	Article	IF	Citations
19	Defining hard-to-reach populations for vaccination. Vaccine, 2019, 37, 5525-5534.	1.7	46
20	The economic impact of substandard and falsified antimalarial medications in Nigeria. PLoS ONE, 2019, 14, e0217910.	1.1	45
21	Sustainability of donor programs: evaluating and informing the transition of a large HIV prevention program in India to local ownership. Global Health Action, 2011, 4, 7360.	0.7	41
22	Global access to quality-assured medical products: the Oxford Statement and call to action. The Lancet Global Health, 2019, 7, e1609-e1611.	2.9	32
23	Systematic review of the incremental costs of interventions that increase immunization coverage. Vaccine, 2018, 36, 3641-3649.	1.7	31
24	Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients. Annals of Pharmacotherapy, 2018, 52, 1031-1041.	0.9	30
25	Trust in the context of community-based health insurance schemes in Cambodia: Villagers' trust in health insurers. Advances in Health Economics and Health Services Research, 2009, , 107-132.	0.2	29
26	Estimating costs of care for meningitis infections in low- and middle-income countries. Vaccine, 2015, 33, A240-A247.	1.7	27
27	A systematic review of the role of pharmacists in vaccination services in low-and middle-income countries. Research in Social and Administrative Pharmacy, 2021, 17, 300-306.	1.5	27
28	Transitioning a Large Scale HIV/AIDS Prevention Program to Local Stakeholders: Findings from the Avahan Transition Evaluation. PLoS ONE, 2015, 10, e0136177.	1.1	26
29	Which Path to Universal Health Coverage? Perspectives on the World Health Report 2010. PLoS Medicine, 2010, 7, e1001001.	3.9	25
30	Monitoring and Evaluating the Transition of Large-Scale Programs in Global Health. Global Health, Science and Practice, 2015, 3, 591-605.	0.6	24
31	Management practices to support donor transition: lessons from Avahan, the India AIDS Initiative. BMC Health Services Research, 2015, 15, 232.	0.9	23
32	Exploring Meaning and Types of Trust in Maternity Care in Peri-Urban Kenya: A Qualitative Cross-Perspective Analysis. Qualitative Health Research, 2018, 28, 305-320.	1.0	22
33	Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1149-1157.	0.6	21
34	Using best-worst scaling to rank factors affecting vaccination demand in northern Nigeria. Vaccine, 2017, 35, 6429-6437.	1.7	19
35	Poor-quality antimalarials further health inequities in Uganda. Health Policy and Planning, 2019, 34, iii36-iii47.	1.0	19
36	Funding gap for immunization across 94 low- and middle-income countries. Vaccine, 2016, 34, 6408-6416.	1.7	17

3

#	Article	IF	CITATIONS
37	COVID-19 Treatments Sold Online Without Prescription Requirements in the United States: Cross-sectional Study Evaluating Availability, Safety and Marketing of Medications. Journal of Medical Internet Research, 2022, 24, e27704.	2.1	16
38	Monitoring and evaluating transition and sustainability of donor-funded programs: Reflections on the Avahan experience. Evaluation and Program Planning, 2015, 52, 148-158.	0.9	15
39	Household Size and the Decision to Purchase Health Insurance in Cambodia: Results of a Discrete-Choice Experiment with Scale Adjustment. Applied Health Economics and Health Policy, 2016, 14, 195-204.	1.0	15
40	Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study. Malaria Journal, 2019, 18, 5.	0.8	15
41	The Avahan Transition: Effects of Transition Readiness on Program Institutionalization and Sustained Outcomes. PLoS ONE, 2016, 11, e0158659.	1.1	15
42	Trust in the context of community-based health insurance schemes in Cambodia: villagers' trust in health insurers. Advances in Health Economics and Health Services Research, 2009, 21, 107-32.	0.2	15
43	The essential role of pharmacists facilitating vaccination in older adults: the case of Herpes Zoster. Human Vaccines and Immunotherapeutics, 2020, 16, 70-75.	1.4	14
44	Importance of medicine quality in achieving universal health coverage. PLoS ONE, 2020, 15, e0232966.	1.1	14
45	Characteristics of online pharmacies selling Adderall. Journal of the American Pharmacists Association: JAPhA, 2021, 61, e103-e109.	0.7	14
46	Howâ€to guide for overcoming barriers of research and scholarship training in Pharm.D. and pharmacy residency programs. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 743-753.	0.5	12
47	The impact of vaccination on gender equity: conceptual framework and human papillomavirus (HPV) vaccine case study. International Journal for Equity in Health, 2020, 19, 10.	1.5	11
48	Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1042-1053.	0.6	11
49	Educational and economic returns to cognitive ability in low- and middle-income countries: A systematic review. World Development, 2022, 149, 105668.	2.6	11
50	Characterizing Medicine Quality by Active Pharmaceutical Ingredient Levels: A Systematic Review and Meta-Analysis across Low- and Middle-Income Countries. American Journal of Tropical Medicine and Hygiene, 2022, 106, 1778-1790.	0.6	11
51	Development and Validation of the Trust in My Doctor, Trust in Doctors in General, and Trust in the Health Care Team Scales. Social Science and Medicine, 2022, 298, 114827.	1.8	10
52	The economic value of increasing geospatial access to tetanus toxoid immunization in Mozambique. Vaccine, 2016, 34, 4161-4165.	1.7	9
53	Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model. BMC Public Health, 2020, 20, 1083.	1.2	9
54	Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	9

#	Article	IF	Citations
55	The economic and social benefits of childhood vaccinations in BRICS. Bulletin of the World Health Organization, 2014, 92, 454-456.	1.5	8
56	Evidence-to-policy gap on hepatitis A vaccine adoption in 6 countries: Literature vs. policymakers' beliefs. Vaccine, 2014, 32, 4089-4096.	1.7	8
57	Cost savings of paper analytical devices (PADs) to detect substandard and falsified antibiotics: Kenya case study. Medicine Access Point of Care, 2021, 5, 239920262098030.	1.0	8
58	Parents' preferences for interventions to improve childhood immunization uptake in northern Nigeria. Vaccine, 2018, 36, 2833-2841.	1.7	7
59	Making the economic value proposition for pharmacist comprehensive medication management (CMM) in primary care: A conceptual framework. Research in Social and Administrative Pharmacy, 2020, 16, 1416-1421.	1.5	7
60	Implementation and Initial Evaluation of a Research and Scholarship Training Pathway in a Doctor of Pharmacy Curriculum. American Journal of Pharmaceutical Education, 2021, 85, 8079.	0.7	7
61	Accessibility of Low-cost Insulin From Illegitimate Internet Pharmacies: Cross-sectional Study. Journal of Medical Internet Research, 2022, 24, e25855.	2.1	7
62	Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in Mozambique. Sexually Transmitted Diseases, 2017, 44, 222-226.	0.8	6
63	Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia. Vaccine, 2021, 39, 6700-6711.	1.7	6
64	Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya. Vaccine, 2019, 37, 2377-2386.	1.7	5
65	A systems map of the economic considerations for vaccination: Application to hard-to-reach populations. Vaccine, 2021, 39, 6796-6804.	1.7	5
66	Building informed trust: developing an educational tool for injection practices and health insurance in Cambodia. Health Policy and Planning, 2018, 33, 1009-1017.	1.0	4
67	Trust in vaccines and medicines in Uganda. Vaccine, 2019, 37, 6008-6015.	1.7	4
68	An investment case for maternal and neonatal tetanus elimination. Vaccine, 2020, 38, 2241-2249.	1.7	4
69	Beyond refill alignment: Evaluating the impact of appointment-based model. Research in Social and Administrative Pharmacy, 2022, 18, 3751-3757.	1.5	4
70	Health versus other sectors: Multisectoral resource allocation preferences in Mukono district, Uganda. PLoS ONE, 2020, 15, e0235250.	1.1	3
71	Modeling the Health and Economic Impact of Substandard and Falsified Medicines: A Review of Existing Models and Approaches. American Journal of Tropical Medicine and Hygiene, 2022, 107, 14-20.	0.6	3
72	Out-of-Pocket Household Expenditures on Medical Injections in Cambodia. PharmacoEconomics - Open, 2018, 2, 415-421.	0.9	2

#	Article	IF	CITATIONS
73	Promoting, seeking, and reaching vaccination services: A systematic review of costs to immunization programs, beneficiaries, and caregivers. Vaccine, 2021, 39, 4437-4449.	1.7	2
74	Online Pharmacy Accessibility of Imatinib, An Oral Chemotherapy Medication. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 808-814.	2.3	2
75	Systematic review of the costs for vaccinators to reach vaccination sites: Incremental costs of reaching hard-to-reach populations. Vaccine, 2021, 39, 4598-4610.	1.7	1
76	15. Villagers' Evaluation of a Community-based Health Insurance Scheme in Thmar Pouk, Cambodia. , 2011, , 365-384.		1
77	Assessing the Impact of Substandard and Falsified Antimalarials in Benin. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	1
78	â€~Decade Of Vaccines': The Authors Reply. Health Affairs, 2011, 30, 2026-2027.	2.5	0
79	Chapter 8: Social Capital and Health in Low- and Middle-Income Countries. World Scientific Series in Global Healthcare Economics and Public Policy, 2014, , 153-175.	0.1	O
80	How-To Guide for Overcoming Barriers of Research and Scholarship Training in Pharm.D. and Pharmacy Residency Programs. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 743-753.	0.5	0
81	Evaluating Real-World Effectiveness and Safety of Generic and Brand-Name Imatinib in Chronic Myeloid Leukemia. Blood, 2021, 138, 3614-3614.	0.6	0
82	An international comparison of physician workforce: how many doctors does it take to make a nation healthy?. The Maryland Medicine: MM: A Publication of MEDCHI Maryland State Medical Society, 2008, 9, 18-21.	0.0	0